PDPaul C. Dimayuga

Paul C. Dimayuga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul C. Dimayuga has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Bojan Cercek

    Oppenheimer Atherosclerosis Research Center, Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, USA

    19 shared publications
  • Kuang-Yuh Chyu

    Oppenheimer Atherosclerosis Research Center, Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, USA

    16 shared publications
  • Prediman K. Shah

    Oppenheimer Atherosclerosis Research Center, Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, USA

    16 shared publications
  • Xiaoning Zhao

    Oppenheimer Atherosclerosis Research Center, Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, USA

    14 shared publications
  • Jianchang Zhou

    Oppenheimer Atherosclerosis Research Center, Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, USA

    13 shared publications
  • Juliana Yano

    Oppenheimer Atherosclerosis Research Center, Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States

    11 shared publications

Latest Publications

  • Open Access

    IRE1 deficiency in myeloid cells increases atherosclerosis in apoE−/− mice

    by Xiaoning Zhao, Jianchang Zhou, Kuang-Yuh Chyu, Bojan Cercek, Ebru Erbay, Prediman K. Shah, Paul C. Dimayuga

  • Open Access

    LL ‐37 IgG levels are associated with clinical characteristics and T follicular cell response in acute coronary syndrome in adults

    by Paul C. Dimayuga, Jianchang Zhou, Xiaoning Zhao, Kuang‐Yuh Chyu, Prediman K. Shah, Bojan Cercek

    Elevated LL‐37 IgG levels are implicated in inflammatory conditions and immune complexes formed with LL‐37 potentially propagate immunothrombosis in acute coronary syndrome (ACS). The reported binding of LL‐37 to LDL may be relevant in this context given that LDL autoantibodies are implicated in ACS risk. In this report, three distinct cohorts were used to evaluate immunologic characteristics, clinical relevance, and potential mechanisms of elevated LL‐37 IgG levels in ACS. First, evaluation of IgG reactive to native (n) LDL and LL‐37 complexed with LDL (LL‐37_LDL) in a cohort without acute disease demonstrated significantly higher levels of LL‐37 IgG compared to LL‐37_LDL IgG and nLDL IgG. Next, evaluation of LL‐37 IgG levels in samples ( N = 500) from the AZACS study (Azithromycin in ACS) and population‐level associations with clinical characteristics showed that LL‐37 IgG levels were significantly higher in subjects who had prior myocardial infarction and were negatively correlated with blood pressure. Third, an ACS cohort showed a negative association of LL‐37 IgG with LVEF. There was also significantly reduced CD8 + CD25 + CXCR5 + T follicular (Tf) regulatory cells with constant CD8 + CD137 + CXCR5 + Tf‐like cells in response to LL‐37 stimulation of peripheral blood mononuclear cells suggesting the association of Tf cells with increased LL‐37 IgG levels in ACS.

  • Open Access

    Adaptive immune response to the autoantigen LL ‐37 differentiates atherosclerotic cardiovascular disease phenotypes

    by Paul C. Dimayuga, Kuang‐Yuh Chyu, Jianchang Zhou, Xiaoning Zhao, Janet Wei, Bojan Cercek, Prediman K. Shah

    Atherosclerosis is the common underlying pathology in atherosclerotic cardiovascular disease (ASCVD) phenotypes of myocardial infarction (MI), stroke or peripheral artery disease (PAD). Single immune cell profiling of atherosclerotic plaques demonstrates a site‐specific immune profile associated with the ASCVD phenotype, and LL‐37 is a reported autoantigen in atherosclerosis. Objective: To investigate whether the immune response to LL‐37 would be common among different ASCVD phenotypes. Methods: Peripheral blood mononuclear cells (PBMCs) and plasma were collected from stable ASCVD patients enrolled within 12 months after MI or stroke or diagnosed with PAD. A subgroup of post‐acute patients provided PBMCs at follow‐up (14.7 ± 3.6 months). T‐cell response to LL‐37 was profiled using activation‐induced markers. LL‐37 IgG, immune complex (IC) levels and subclass were evaluated with ELISA. LDL is a reported binding partner of LL‐37 in plasma. Therefore, cross‐reactivity of LL‐37 IgG‐ICs with native LL‐37 or LL‐37 complexed with LDL (LL‐37_LDL) was assessed using immune depletion. Results: LL‐37 provokes increased CD4 + CD25 + CD134 + T‐cell response in stable post‐MI patients whereas CD8 + CD25 + CD69 + T cells were reduced in PAD. CD4 + T‐cell response to LL‐37 in post‐MI patients persisted at follow‐up with increased CD4 + CD25 + CD69 + FoxP3 + T regulatory cells while post‐stroke patients had increased CD8 + CD134 + T cells. LL‐37 IgG‐ICs were significantly increased in ASCVD patients with IgG3 subclass reduced in post‐MI compared to post‐stroke. Immune‐depletion showed cross‐reactivity of LL‐37 IgG‐ICs with both native LDL and LL‐37_LDL only in post‐MI plasma. Conclusion: LL‐37 antigen specific profiling of immune response may differentiate various ASCVD phenotypes and provide mechanistic insight in pathophysiology.

  • Open Access

    Myeloid Fmr1 deficiency in mice results in reduced serum cholesterol and altered bile pathway gene expression

    by Xiaoning Zhao, Jianchang Zhou, Kuang-Yuh Chyu, Ebru Erbay, Bojan Cercek, Prediman K. Shah, Paul C. Dimayuga

    Fragile X Syndrome (FXS) is a genetic disorder caused by increased CGG repeats in the Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene which encodes an RNA-binding protein that can alter mRNA processing, translation and stability. Among the effects of FMRP deficiency is the modulation of metabolic pathway gene expression resulting in reduced cholesterol. In this report, the role of Fmr1 in modulating serum cholesterol of mice fed Western diet was investigated. Fmr1-KO mice had reduced serum cholesterol that occurred even as LDLR expression was reduced, suggesting a non-LDLR pathway of cholesterol clearance. Hepatic bile synthesis gene expression was altered in the Fmr1-KO mice. Given the reports of myeloid cell modulation of liver function, myeloid specific Fmr1 deficiency was investigated. Reduced serum cholesterol was replicated in myeloid-specific deficiency of Fmr1. Myeloid-specific deficient Fmr1 female mice had significantly increased Cyp27a1 while male mice had significantly increased Cyp7b1, yet no differences were observed in serum bile acid levels. Evaluation of bile transporter expression demonstrated that female mice with myeloid Fmr1 deficiency had significantly increased expression of Ntcp and Slco1b2, while myeloid Fmr1 deficient male mice had significantly increased Slco1a1. The sulfonating enzyme Sult2a8 was increased in both female and male mice suggesting some commonality in the pathway, but over-expression of Sult2a8 in Western diet fed wild type mice did not alter serum cholesterol. However, liver expression of the bile acid membrane G protein coupled receptor Tgr5 was significantly increased in myeloid Fmr1 deficient mice suggesting a novel interaction between the Fmr1 gene and Tgr5.

  • Open Access

    A Novel Pathway of Platelet Activation in ACS Mediated by LL-37 Immunoglobulin G Autoantibody Immune Complexes

    by Paul C. Dimayuga, Kuang-Yuh Chyu, Xiaoning Zhao, Jianchang Zhou, Nicole Wai Man Lio, Fernando Chernomordik, Daniel Berman, Prediman K. Shah, Bojan Cercek


  • Open Access

    Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome

    by Fernando Chernomordik, Bojan Cercek, Jianchang Zhou, Xiaoning Zhao, Nicole Wai Man Lio, Kuang-Yuh Chyu, Prediman K. Shah, Paul C. Dimayuga

    Background: LL-37 is the only member of the cathelicidin family of antimicrobial peptides in humans and is an autoantigen in several autoimmune diseases and in acute coronary syndrome (ACS). In this report, we profiled the specific T cell response to the autoimmune self-antigen LL-37 and investigated the factors modulating the response in peripheral blood mononuclear cells (PBMCs) of healthy subjects and ACS patients.Methods and results: The activation induced marker (AIM) assay demonstrated differential T cell profiles characterized by the persistence of CD134 and CD137, markers that impair tolerance and promote immune effector and memory response, in ACS compared to Controls. Specifically, CD8+CD69+CD137+ T cells were significantly increased by LL-37 stimulation in ACS PBMCs. T effector cell response to LL-37 were either HLA dependent or independent as determined by blocking with monoclonal antibody to either Class-I HLA or Class-II HLA. Blocking of immune checkpoints PD-1 and CTLA-4 demonstrated the control of self-reactive T cell response to LL-37 was modulated predominantly by CTLA-4. Platelets from healthy controls down-modulated CD8+CD69+CD137+ T cell response to LL-37 in autologous PBMCs. CD8+CD69+CD137+ T cell AIM profile negatively correlated with platelet count in ACS patients.Conclusions: Our report demonstrates that the immune response to the autoantigen LL-37 in ACS patients is characterized specifically by CD8+CD69+CD137+ T cell AIM profile with persistent T cell activation and the generation of immunologic memory. The results provide potentially novel insight into mechanistic pathways of antigen-specific immune signaling in ACS.


  • Open Access

    Immunization using ApoB-100 peptide–linked nanoparticles reduces atherosclerosis

    by Kuang-Yuh Chyu, Xiaoning Zhao, Jianchang Zhou, Paul C. Dimayuga, Nicole W.M. Lio, Bojan Cercek, Noah T. Trac, Eun Ji Chung, Prediman K. Shah

    Active immunization with the apolipoprotein B-100 (ApoB-100) peptide P210 reduces experimental atherosclerosis. To advance this immunization strategy to future clinical testing, we explored the possibility of delivering P210 as an antigen using nanoparticles, given this approach has been used clinically. We first characterized the responses of T cells to P210 using PBMCs from patients with atherosclerotic cardiovascular disease (ASCVD). We then investigated the use of P210 in self-assembling peptide amphiphile micelles (P210-PAMs) as a vaccine formulation to reduce atherosclerosis in B6.129P2-Apoe tm1Unc /J ( ApoE –/– ) mice and P210’s potential mechanisms of action. We also generated and characterized a humanized mouse model with chimeric HLA-A*02:01/Kb in ApoE –/– background to test the efficacy of P210-PAM immunization as a bridge to future clinical testing. P210 provoked T cell activation and memory response in PBMCs of patients with ASCVD. Dendritic cell uptake of P210-PAM and its costaining with MHC-I molecules supported its use as a vaccine formulation. In ApoE –/– mice, immunization with P210-PAMs dampened P210-specific CD4 + T cell proliferative response and CD8 + T cell cytolytic response, modulated macrophage phenotype, and significantly reduced aortic atherosclerosis. Potential clinical relevance of P210-PAM immunization was demonstrated by reduced atherosclerosis in the humanized ApoE –/– mouse model. Our data support experimental and translational use of P210-PAM as a potential vaccine candidate against human ASCVD.


  • Open Access

    The Role of T Cells Reactive to the Cathelicidin Antimicrobial Peptide LL-37 in Acute Coronary Syndrome and Plaque Calcification

    by Fernando Chernomordik, Bojan Cercek, Wai Man Lio, Peter M. Mihailovic, Juliana Yano, Romana Herscovici, Xiaoning Zhao, Jianchang Zhou, Kuang-Yuh Chyu, Prediman K. Shah, et al.

    The human cationic anti-microbial peptide LL-37 is a T cell self-antigen in patients with psoriasis, who have increased risk of cardiovascular events. However, the role of LL-37 as a T cell self-antigen in the context of atherosclerosis remains unclear. The objective of this study was to test for the presence of T cells reactive to LL-37 in patients with acute coronary syndrome (ACS). Furthermore, the role of T cells reactive to LL-37 in atherosclerosis was assessed using apoE−/− mice immunized with the LL-37 mouse ortholog, mCRAMP. Peripheral blood mononuclear cells (PBMCs) from patients with ACS were stimulated with LL-37. PBMCs from stable coronary artery disease (CAD) patients or self-reported subjects served as controls. T cell memory responses were analyzed with flow cytometry. Stimulation of PBMCs with LL-37 reduced CD8+ effector T cell responses in controls and patients with stable CAD but not in ACS and was associated with reduced programmed cell death protein 1 (PDCD1) mRNA expression. For the mouse studies, donor apoE−/− mice were immunized with mCRAMP or adjuvant as controls, then T cells were isolated and adoptively transferred into recipient apoE−/− mice fed a Western diet. Recipient mice were euthanized after 5 weeks. Whole aortas and hearts were collected for analysis of atherosclerotic plaques. Spleens were collected for flow cytometric and mRNA expression analysis. Adoptive transfer experiments in apoE−/− mice showed a 28% reduction in aortic plaque area in mCRAMP T cell recipient mice (P < 0.05). Fifty six percent of adjuvant T cell recipient mice showed calcification in atherosclerotic plaques, compared to none in the mCRAMP T cell recipient mice (Fisher’s exact test P = 0.003). Recipients of T cells from mice immunized with mCRAMP had increased IL-10 and IFN-γ expression in CD8+ T cells compared to controls. In conclusion, the persistence of CD8+ effector T cell response in PBMCs from patients with ACS stimulated with LL-37 suggests that LL-37-reactive T cells may be involved in the acute event. Furthermore, studies in apoE−/− mice suggest that T cells reactive to mCRAMP are functionally active in atherosclerosis and may be involved in modulating plaque calcification.


  • Open Access

    Sex as a Determinant of Responses to a Coronary Artery Disease Self-Antigen Identified by Immune-Peptidomics

    by Wai Man Lio, Bojan Cercek, Juliana Yano, Wei Yang, Jonathan Ghermezi, Xiaoning Zhao, Jianchang Zhou, Bo Zhou, Michael R. Freeman, Kuang-Yuh Chyu, et al.

    A significant body of work implicates the adaptive immune response in atherosclerosis, the main underlying cause of coronary artery disease (CAD), yet specific antigens involved remain to be fully identified. The pathobiology of CAD is influenced by sex with many factors that may be involved in the underlying mechanisms. Given the reported sexual dimorphic nature of immune-inflammatory responses, we investigated the influence of sex on potential CAD self-antigens from acute coronary syndrome (ACS) patients using immune-precipitation of soluble HLA Class-I/peptide complexes and mass spectrometry. Relevance of identified self-antigens to atherosclerosis, the major underlying cause of CAD, was tested in the apoE–/– atherosclerotic mouse model. Soluble HLA Class-I complexes from ACS patients and self-reported controls were immune-precipitated and subjected to elution, denaturation and size-exclusion to obtain HLA-bound peptides. Peptides were then subjected to mass spectrometry and patient-unique self-peptides were grouped as common to both female and male, or unique to either sex. Three peptides common to both female and male patients (COL6A1, CDSN, and SAA2), and 2 peptides each unique to female (COL1A1 and COL5A2) or male (SAA1 and KRT 9) patients were selected and mouse homologs of the peptides were screened for self-reactive immune responses in apoE–/– mice. The screening step revealed potential sex-influenced immune responses which was associated with differential immune profiles. Based on the frequency in patient plasma, COL6A1, COL5A2, and KRT 9 peptides were then tested in immunization studies. Neither COL5A2 nor KRT 9 peptide immunization resulted in significant effects on atherosclerosis compared to controls. On the other hand, female mice immunized with COL6A1 peptide had significantly reduced atherosclerosis whereas male mice had significantly increased atherosclerosis, associated with differential immune profiles. Our study identified potential self-antigens involved in atherosclerosis using the immune peptidome of CAD patients. Altering self-reactive immune responses to COL6A1 in apoE–/– mice resulted in differential effects on atherosclerosis burden with sex as a determinant of outcome.


  • Open Access

    IL-7R blockade reduces post-myocardial infarction-induced atherosclerotic plaque inflammation in ApoE−/- mice

    by Peter M. Mihailovic, Wai Man Lio, Juliana Yano, Jianchang Zhou, Xiaoning Zhao, Kuang-Yuh Chyu, Prediman K. Shah, Bojan Cercek, Paul C. Dimayuga